1 citations
,
January 2022 in “European Journal of Pharmacology” In this study, FMN was found to inhibit androgen receptor function and androgen-regulated gene expression in prostate cancer cells, suggesting potential as an antiandrogen therapy.
8 citations
,
January 2011 in “International journal of trichology” This report discusses the accurate diagnosis of atrichia with papular lesions, emphasizing its distinction from alopecia universalis to prevent unnecessary steroid treatment, and presents a case matching APL diagnostic criteria.
February 2024 in “Scientific reports” This study identified four ferroptosis-related genes, SLC40A1, LCN2, CREB5, and SLC7A11, as potential diagnostic markers for alopecia areata, revealing reduced expression in affected patients compared to controls, with a predictive model showing high accuracy in differentiating the condition.
1 citations
,
December 2017 in “Anais Brasileiros de Dermatologia” This article discusses the DOAJ, a comprehensive index of international open access journals, and emphasizes its role in providing free quality content online without presenting new research findings.
6 citations
,
June 2019 in “International Journal of Dermatology” This article discusses familial frontal fibrosing alopecia in two male families and reports no new clinical findings.
April 2019 in “Journal of Investigative Dermatology” This study found that frontal fibrosing alopecia involves distinct molecular changes, such as downregulation of steroid and cholesterol pathways and upregulation of fibrotic and immune response genes, which may help guide treatment strategies.
April 2023 in “Journal of Investigative Dermatology” This study explores how chromatin differences between dermal papilla cells and papillary fibroblasts contribute to hair follicle inductivity and investigates the regulatory changes in androgenic alopecia.
2 citations
,
January 2016 in “Dermatology online journal” This case report describes a 46-year-old man diagnosed with frontal fibrosing alopecia, a condition primarily affecting postmenopausal women, highlighting its rare occurrence in men.
4 citations
,
July 2020 in “Research Square (Research Square)” This study provided the crystal structure of the human steroid 5α-reductase 2 enzyme and identified key molecular mechanisms for testosterone reduction and finasteride inhibition, aiding in understanding disease-causing mutations and potentially facilitating new drug development.
20 citations
,
August 2005 in “Journal of Cutaneous Pathology” This study found that in male androgenic alopecia, the androgen receptor coactivator ARA70/ELE1 exhibits differential expression patterns, suggesting its involvement in the condition.
February 2009 in “RePub (Erasmus University Rotterdam)” This thesis investigates the role of phosphorylation and the mutation F826L in modulating androgen receptor activity, but concludes that the precise effects are not yet fully clear.
1 citations
,
November 2003 in “Humana Press eBooks” This article discusses the use of atomic force microscopy for examining human hair surfaces in dermatology, cosmetics, and forensic science, but presents no new research findings.
2 citations
,
October 2000 in “Journal of Investigative Dermatology” AUC and APL are distinct conditions needing careful clinical assessment.
1 citations
,
October 2000 in “Journal of Investigative Dermatology” The Thr1022Ala variant in the hairless gene is not a disease-causing mutation.
33 citations
,
September 2014 in “Reproductive Biology and Endocrinology” In this study, elevated afamin concentrations were associated with metabolic syndrome in young women, particularly those with insulin resistance, suggesting a potential predictive role for afamin in metabolic risk assessment.
14 citations
,
January 2017 in “Pharmacological Reports” TP0427736 may help treat hair loss by blocking a specific protein and promoting hair growth.
180 citations
,
February 2023 in “Journal of Chemical Information and Modeling” In this paper, Chemistry42—a software integrating AI with computational and medicinal chemistry—demonstrated efficiency in designing novel molecular structures targeting DDR1 and CDK20, with properties validated in both in vitro and in vivo studies.
24 citations
,
November 2023 in “Regenerative Biomaterials” In this review, the authors summarized the potential therapeutic effects of metal ions in treating cardiovascular diseases, highlighting their roles in protecting cells, inducing angiogenesis, and adjusting ion channel functions, as well as discussing delivery strategies involving biomaterials.
16 citations
,
March 2022 in “Archives of Toxicology” This review summarizes recent advancements in therapies targeting botulinum neurotoxin, emphasizing human monoclonal antibodies and clinical research, but provides no new clinical findings.
15 citations
,
November 2024 in “Pharmaceutics” This review discusses how recent advancements in computational and lab-based methods have enhanced peptide drug discovery, noting the efficiency and cost benefits over traditional approaches and the potential for targeting difficult protein interactions, including protein degradation using proteolysis-targeting chimeras.
12 citations
,
June 2025 in “Gut Microbes” This study developed BroadAMP-GPT, a computational-experimental framework, to discover new antimicrobial peptides, identifying candidates effective against multidrug-resistant pathogens. Notably, AMP_S13 showed strong stability, low toxicity, and efficacy in infection models, highlighting the platform's potential in combating antimicrobial resistance.
7 citations
,
May 2025 in “Journal of Biomedical Science” This study found that KRT6A expression increases after epidermal barrier disruption, worsening skin inflammation in disease conditions, and suggests that targeting KRT6A could offer a new treatment approach for inflammatory skin diseases linked to epidermal dysfunction.
7 citations
,
January 2025 in “Journal of Experimental & Clinical Cancer Research” This study found that PRMT5 inhibitors showed potent anti-tumor activity in models of adenoid cystic carcinoma and that combining these inhibitors with lenvatinib may have additional growth-inhibitory effects.
6 citations
,
August 2024 in “BMC Ophthalmology” This study identified multiple genetic variants in Pakistani families with oculocutaneous albinism, including two novel variants, enhancing understanding of its genetic basis and aiding better management and counseling.
6 citations
,
July 2024 in “Heliyon” This study examined the evolutionary and functional homology of steroid 5α-reductase and DET2 proteins, identifying protists as a common ancestor, and discovered a new subclass DET2-like in plants, potentially involved in polyprenol reduction.
5 citations
,
January 2025 in “Burns & Trauma” This review highlights recent research using single-cell RNA sequencing and machine learning in wound healing, revealing significant insights into fibroblast diversity, immune cell dynamics, and the spatial organization of cells, which may transform therapeutic strategies for chronic wounds, fibrosis, and tissue regeneration.
4 citations
,
June 2025 in “MedComm” This review detailed the significant progress and challenges in the design and application of PROTACs, a novel class of cancer therapeutics, highlighting their clinical trials, design complexities, and the role of artificial intelligence in improving their efficacy and selectivity for cancer therapy.
4 citations
,
December 2024 in “European Journal of Medicinal Chemistry” This study reported the development of new pyrazole-based MPC inhibitors that effectively inhibit mitochondrial pyruvate transport, showing potential as therapeutic candidates for conditions like metabolic dysfunction-associated steatohepatitis without activating PPARγ.
4 citations
,
November 2024 in “International Journal of Molecular Sciences” This review explores whether SARS-CoV-2 could trigger or worsen α-synucleinopathies, like Parkinson's disease, by affecting α-synuclein misfolding and aggregation, potentially linking COVID-19 with the development of parkinsonism-like symptoms.
3 citations
,
May 2024 in “BMC Medical Genomics” This study is the first to identify a de novo heterozygous frameshift insertion variant in the ARID1B gene as a cause of Coffin-Siris syndrome with an association to excessive early-onset high myopia.